Introduction The effects of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) on CMV infection in patients with autoimmune diseases receiving immunosuppressants have not been explored. Methods Patients with active systemic lupus erythematosus (SLE) were preemptively monitored for clinically significant CMV infection (CsCMVI, defined as plasma CMV DNA loads > 3 log10 IU/mL). CMV-specific CMI was assessed using an enzyme-linked immunosorbent assay (QuantiFERON-CMV®, QF) before as well as 1 and 3 months after intense immunosuppressive therapy. Results The study included 55 patients with active SLE; patients had a mean age of 34 years (standard deviation [SD] 13 years), a median SLEDAI-2K score of 14 (SD 8), and 93% were female. Most patients had renal involvement (67%), received methylprednisolone (93%), and were CMV seropositive (95%). Thirteen (23.6%) patients developed CsCMVI. Among patients with active SLE who were QF-negative (QF–) and QF-positive (QF+) before receiving immunosuppressive therapy, 28.6% and 25% developed CsCMVI, respectively (p=0.69). However, 1 month post-immunosuppression, more QF– than QF+ patients developed CsCMVI (44.4% vs. 11.8%, p=0.03; adjusted hazard ratio 4.97 [95% confidence interval 1.07–23.10], p=0.04). Conclusions Patients with active SLE and low CMV-specific T cell responses could develop CMV infection after receiving immunosuppressants. Further studies should focus on CMV-specific CMI among patients with autoimmune diseases.
Background Cytomegalovirus (CMV) infection has been emerging among autoimmune disease patients. CMV-specific cellular immunity has been shown to be correlated with CMV clearance in transplant recipients, however, this correlation has not been assessed in autoimmune disease patients. We aimed to investigate the epidemiology and clinical variables of CMV infection focused on CMV-specific cellular response of CMV infection in active systemic lupus erythematosus (SLE) patients receiving immunosuppressant. Methods A prospective cohort study of active SLE patients who received immunosuppressant and underwent preemptively monitored for CMV infection by quantitative real-time PCR (Abbott RealTime CMV assay). Clinical variables were collected. CMV-specific cellular immune responses were measured by an enzyme-linked immunosorbent assay (QuantiFERON-CMV®) and intracellular cytokine assay. Clinically significant CMV infection was defined as CMV disease or plasma CMV DNA loads > 1,000 IU/mL. Results We included 45 active SLE patients in our cohort. Among 39 evaluable patients, there were 36 (92%) female patients with a median age of 28 (IQR 24-44) years. A median SLEDAI score was 16 (IQR 9-20). Seventy-four % had renal involvement. Methylprednisolone was the most common immunosuppressive regimen (94.9%). Thirty-six (92.3%) patients were CMV-seropositive. Clinically significant CMV infection occurred in 6 (25.6%) patients included asymptomatic CMV infection (79.3%), CMV syndrome (17.3%), and CMV tissue invasive disease (3.4%). Among 197 blood samplings, there were 16 (8.1%) episodes of clinically significant CMV infection. The distributions of QuantiFERON-CMV® status were reactive, non-reactive and indeterminate (33% vs. 44% vs. 22%; p = 0.56), respectively. The percentage of CMV-IE1-specific NKT cells in those with clinically significant CMV infection were lower than those without infection (0.18% vs. 1.93%, p = 0.03). In multivariate analysis, neurological involvement was associated with clinically significant CMV infection (OR 7.9; 95% CI 1.5-41.9, [p = 0.015]). Conclusion Active SLE patients with neurological involvement who received intense immunosuppression are at risk of CMV infection. Lack of CMV-specific NKT cell response tends to be associated with CMV infection. Disclosures All Authors: No reported disclosures
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.